Previous studies have demonstrated that the 21-gene RS may have less prognostic accuracy in Black women.13,14,15 Uncertainty exists regarding the applicability of RS in key high-risk subgroups of patients with early-stage HR-positive, ERBB2-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.